Physician

Daniel Muller, MD PHD

According to 2025 Medicare claims, Daniel Muller, MD PHD (NPI: 1073589016) practices rheumatology in the Fort Collins-Loveland, CO market, with the plurality of this provider's patient population coming from Larimer, CO. This provider's primary affiliated billing organization is POUDRE VALLEY MEDICAL GROUP, LLC (NPI: 1366763260; TIN: 800348943) and primary practice location at 80538-9004. Muller is affiliated with the Caravan Collaborative Pathways (ACO ID: A4604), Banner Network Colorado, LLC (ACO ID: A4768), and CoreHealth Alliance LLC (ACO ID: A5645), participating under the MSSP model.

Muller's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 290 traditional Medicare patients, billed 24,945 HCPCS/CPT codes, and received $440,120 in Medicare payments. The top billing code was 99204 (New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more). Part D data shows 1,819 prescription claims across 357 beneficiaries totaling $2,281,128 in drug costs, led by Humira(Cf) Pen (Adalimumab). Open Payments data shows 1 records totaling $88. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $29,243 and ending at $440,120. Concurrently, Part D prescription costs have risen steadily, from $582,494 to $2,281,128. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	306	1,153	$29,243
2016	234	1,144	$37,492
2017	144	2,237	$91,040
2018	471	35,815	$832,158
2019	339	19,490	$698,680
2020	298	22,390	$619,680
2021	326	39,465	$819,459
2022	337	49,825	$789,734
2023	335	26,458	$508,544
2024	290	24,945	$440,120

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	170	1,318	$582,494
2016	180	1,065	$760,838
2017	161	510	$248,442
2018	387	1,584	$1,399,524
2019	349	1,828	$1,897,468
2020	357	2,003	$2,159,409
2021	330	1,976	$2,156,637
2022	368	1,966	$2,213,397
2023	345	1,955	$2,530,831
2024	357	1,819	$2,281,128

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	67	67	$127
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	217	379	$92
J0897	Injection, denosumab, 1 mg	17	1,380	$21
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	16	16	$12
96372	Injection of drug or substance under skin or into muscle	22	42	$10

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Humira(Cf) Pen	Adalimumab	90	2,548	$752,343
Enbrel Sureclick	Etanercept	25	840	$233,656
Xeljanz	Tofacitinib Citrate	33	990	$209,306
Gammagard Liquid	Immun Glob G(Igg)/Gly/Iga Ov50	13	364	$173,506
Enbrel	Etanercept	14	588	$149,483

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	1	$88	GENZYME CORPORATION
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Daniel Muller, MD PHD?

Tedicare shows public-source Medicare data for Daniel Muller, MD PHD (NPI 1073589016), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Daniel Muller, MD PHD have ACO affiliation data?

Daniel Muller, MD PHD is shown with ACO affiliation data for Caravan Collaborative Pathways (MSSP, ACO ID A4604), Banner Network Colorado, LLC (MSSP, ACO ID A4768), and CoreHealth Alliance LLC (MSSP, ACO ID A5645).

What billing organization is linked to Daniel Muller, MD PHD?

Daniel Muller, MD PHD is linked to POUDRE VALLEY MEDICAL GROUP, LLC (billing NPI 1366763260) in the available physician profile data.

Does Daniel Muller, MD PHD have Open Payments data?

Daniel Muller, MD PHD has 1 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.